Crossing the BBB is great but it’s not the first oz biotech to do it and others across the globe, it’s about whether it’s better than how others have. Still early days still in the lab preclinical but definitely an intersting path ahead. It’s all time and patience anything in the lab has a long road ahead.
Ann: PAT-DX1 Crosses Blood Brain Barrier to Reduce Tumour Size, page-54
-
- There are more pages in this discussion • 114 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.172M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 37 | 34533848 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 25555974 | 16 |
View Market Depth
| Last trade - 16.12pm 15/10/2024 (20 minute delay) ? |
| PAB (ASX) Chart |
Day chart unavailable